OxyContin Buyers Resolve Purdue Antitrust Claims
Six plaintiffs seeking to certify indirect purchaser classes in multidistrict litigation accusing Purdue Pharma LP of excluding generic competition for the painkiller OxyContin by engaging in sham patent infringement litigation have...To view the full article, register now.
Already a subscriber? Click here to view full article